Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation

SUMMARY Background Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation. Aim To assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation. Methods 195 irritable bowel syndrome with constipation patients received daily doses of 16 [8 lg twice daily (b.d.)], 32 (16 lg b.d.) or 48 lg (24 lg b.d.) lubiprostone or placebo b.d. for 3 months. Gastrointestinal parameters were recorded in diaries daily by patients. Results